Recurrent Or Metastatic Solid Tumors clinical trials

Explore recruiting recurrent or metastatic solid tumors clinical trials.

Recruiting recurrent or metastatic solid tumors studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Recurrent Or Metastatic Solid Tumors trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1b/2 pan-tumor, open-label study to evaluate the efficacy and safety of ifinatamab deruxtecan (I DXd) in subjects with recurrent or metastatic solid tumors

Italy, France, Poland, Germany, Spain, Belgium +3 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1/2, First-In-Human, Multi-Part, Open Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

France, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase II, Single-Arm, Open-Label Study Evaluating the Safety and Pharmacokinetics of the Intravenous Fixed‑Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants with Locally Advanced, Recurrent or Metastatic Solid Tumors

Cyprus, Croatia, Spain, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

Denmark, Netherlands, Belgium, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Recurrent Or Metastatic Solid Tumors trials by city

Recurrent Or Metastatic Solid Tumors in Toronto Recurrent Or Metastatic Solid Tumors in Vancouver Recurrent Or Metastatic Solid Tumors in Montreal Recurrent Or Metastatic Solid Tumors in Calgary Recurrent Or Metastatic Solid Tumors in Edmonton Recurrent Or Metastatic Solid Tumors in Ottawa Recurrent Or Metastatic Solid Tumors in Winnipeg Recurrent Or Metastatic Solid Tumors in Quebec City Recurrent Or Metastatic Solid Tumors in Hamilton Recurrent Or Metastatic Solid Tumors in Kitchener Recurrent Or Metastatic Solid Tumors in London Recurrent Or Metastatic Solid Tumors in Halifax Recurrent Or Metastatic Solid Tumors in New York Recurrent Or Metastatic Solid Tumors in Los Angeles Recurrent Or Metastatic Solid Tumors in Chicago Recurrent Or Metastatic Solid Tumors in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease